4,901 trials
Human Immunodeficiency Virus (HIV) Infection
Primary: Area Under the Concentration-Time Curve From Zero to 24 Hours After Dosing (AUC0-24) of R-Methadone — 55.8; 53.2 ng*hr/mL/mg
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Mild-Moderate Alzheimer's Disease · Healthy Elderly
Primary: Tolerability as Measured by Participant Withdrawal for an Adverse Event — 0; 0; 0; 0 Participants
Stage IV Breast Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (Defined as an Adverse Event of Grade 3 or Higher) — 0; 0 participants
Pulmonary Disease, Chronic Obstructive
Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of Nemiralisib in Plasma — 3199.0; 6272.7 Hours*picogram per…
Breast Cancer · Breast Cancer - Female · Breast Cancer - Male
Primary: Recommended Phase II Dose (RP2D) — 400 dose in mg
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 25354.4; 28896.8; 28684.8 h·μg/mL
Hypercholesterolemia
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) — 175.9; 198.9; 160.3 micrograms*day/milliliter (mcg*day/mL)
B-cell Follicular Lymphoma · B-cell Marginal Zone Lymphoma · Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants
Asthma
Primary: Part A: Number of Participants With Any Non-serious Adverse Event (nSAE) and Any Serious Adverse Event (SAE) — 6; 9; 6; 7 Participants
Thrombosis
Primary: The Number of Subjects With Treatment-related Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. — 1; 3; 1; 2 Participants
Healthy
Primary: Changes in [11C]-(+)-PHNO Binding (Measured as Binding Potential) in Dorsal Caudate (DC) — 2.1 binding potential
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Safety · Healthy Subjects
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 4; 2; 5 Participants
Spinal Muscular Atrophy 1
Primary: Number of Participants That Experienced One Grade III or Higher Unanticipated, Treatment-related Toxicity That Presents With Clinical Symptoms and Requires Medical…